^(125)I放射性籽源植入术联合内分泌疗法治疗前列腺癌的疗效评价(附29例报告)

Intraoperative ^(125)I Brachytherapy Combined with Endocrinotherapy for Prostate Carcinoma(Report of 29 Cases)

目的:初步评价^(125)I放射性籽源植入术联合内分泌疗法治疗前列腺癌的临床疗效。方法:应用术中经直肠超声引导及治疗计划系统软件经会阴穿刺植入^(125)I放射性籽源并同期行手术去势或药物去势治疗前列腺癌患者29例。结果:术后6个月～5年随访,发现29例患者前列腺体积及前列腺特异抗原(PSA)均有不同程度降低,8例淋巴结转移患者及4例骨转移患者转移灶均缩小,术前骨痛及排尿症状均有好转,且无一例出现尿潴留及便血等严重并发症。结论:^(125)I放射性籽源植入术并内分泌疗法对各期前列腺癌均有明显的治疗作用,是一种安全有效的前列腺癌综合治疗手段。

Objective：To evaluate the efficacy, side effects and prognosis of prostate carcinoma treated with intraoperative 125I brachytherapy combined with endocrinotherapy. Methods： 29 patients with prostate carcinoma were treated with intraoperative 125I brachytherapy implanted through perineum under B-ultrasound and system therapy soft guidance and then combined with castration with operation or medicine. Results： The follow-up was from 6 month to five year, 29 patients were found that prostate volume and PSA were reduced at different level. Eight of 29 patients with lymphatic metastasis and four of 29 patients with metastatic carcinoma of bone were found that metastatic carcinoma was reduced and then osteodynia and dysuria were significantly improved. Moreo- ver, no one of 29 cases was induced serious complication such as urinary retention or hematoehezia. Conclusions： 125I brachytherapy combined with endocrinotherapy had significant therapeutic effect for prostate carcinoma with dif- ferent stage. It was a safety and efficient therapy for prostate carcinoma.